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Abstract
 
Previous studies of osteopetrotic (
 
op
 
) mice lacking mac-
rophage colony-stimulating factor (M-CSF) have revealed
an inhibition of atherosclerosis development in the apolipo-
protein E (apo E)-deficient model and in a diet-induced
model. Using LDL receptor–deficient mice, we now show
that atheroma development depends on M-CSF concentra-
tion, as not only did homozygous osteopetrotic (
 
op
 
/
 
op
 
) mice
 
have dramatically reduced lesions (
 
z 
 
0.3% of control lesion
 
size) but heterozygous (
 
op
 
/
 
1
 
) mice had lesions 
 
,
 
 1% of con-
trols. Mice heterozygous for the 
 
op
 
 mutation (
 
op
 
/
 
1
 
) had
plasma levels of M-CSF about half those in controls (
 
1
 
/
 
1
 
).
The finding that an 
 
z
 
 2-fold reduction in M-CSF expres-
sion reduced lesion size 
 
z
 
 100-fold suggests the requirement
for a threshold level of M-CSF. The effect of M-CSF on ath-
erosclerosis did not appear to be mediated either by changes
in plasma lipoprotein levels or alterations in the number of
circulating monocytes, since both 
 
op
 
/
 
op
 
 and 
 
op
 
/
 
1
 
 mice ex-
hibited higher levels of atherogenic lipoprotein particles and
(
 
op
 
/
 
1
 
) mice showed a near normal number of circulating
monocytes. LDL receptor–null littermates of genotypes
from 
 
op
 
/
 
op
 
, 
 
op
 
/
 
1
 
, to 
 
1
 
/
 
1
 
 showed monocyte differentials of
 
z
 
 4.5, 8, and 10%, respectively. Taken together, these re-
sults suggest that the effects of M-CSF on atherogenesis
may not be mediated by expression of M-CSF systemically
or by modulation of the number of circulating monocytes.
These studies support the conclusion that M-CSF partici-
pates critically in fatty streak formation and progression to
a complex fibrous lesion. (
 
J. Clin. Invest. 
 
1998. 101:2702–
 
2710.) Key words: hypercholesterolemia 
 
•
 
 atherogenesis 
 
•
 
osteopetrosis 
 
•
 
 monocytes 
 
•
 
 macrophages
 
Introduction
 
Recruitment, activation, survival, and proliferation of mono-
nuclear phagocytes in the vessel wall contribute importantly to
atherosclerosis (1–3). Several adhesion molecules, chemotactic
cytokines, and growth factors may orchestrate these events in
atherosclerosis (2, 3). Accumulating evidence suggests that
 
macrophage-colony stimulating factor (M-CSF)
 
1
 
 can play a
key role in this process. M-CSF selectively regulates the
growth and survival of mononuclear phagocytes by binding
 
to a specific cell surface receptor, 
 
c-fms
 
 (4–8). In addition,
M-CSF functions as a chemotactic factor for monocytes, regu-
lates the effector functions of mature monocytes and macro-
phages, and modulates inflammatory responses by stimulating
the production of other cytokines and growth factors (4, 9, 10).
Atherosclerotic lesions derived from humans and rabbits con-
tain elevated levels of M-CSF mRNA and immunoreactive
protein (11–13). Atherogenic oxidized LDLs induce aortic en-
dothelial and smooth muscle cell expression of M-CSF, in part
 
through activation of nuclear factor-
 
k
 
B (11, 14, 15). Macro-
phages proliferate within atherosclerotic lesions (16, 17). M-CSF
stimulates proliferation of monocyte precursors and is impor-
tant for the survival of macrophages in culture and in vivo
(4–8). Thus, the localized expression of M-CSF within the ves-
sel wall may be critical in promoting the survival of lipid-laden
foam cells observed in early and advanced stages of atheroscle-
rosis. M-CSF also regulates systemic lipoprotein levels by en-
hancing the clearance of LDL through both LDL receptor
(LDLR)-dependent and -independent pathways (18–21).
M-CSF stimulates cholesterol esterification in human mono-
cyte-derived macrophages and modulates lipoprotein lipase
secretion in macrophages (22, 23). The ability of M-CSF to en-
hance the uptake and degradation of modified lipoproteins by
upregulating scavenger receptor may contribute to the re-
moval of oxidized lipoproteins from extracellular spaces and
the generation of foam cells (12, 24).
Osteopetrotic (
 
op
 
/
 
op
 
) mice that lack M-CSF due to a point
mutation in the M-CSF gene have proven to be useful in exam-
ining the role of M-CSF in the growth and function of mono-
nuclear cells in vivo (25–29). Lack of M-CSF in 
 
op
 
/
 
op
 
 mice re-
sults in impaired growth and differentiation of monocytes and
their precursors in bone marrow, causing a deficiency of blood
monocytes and peritoneal and tissue macrophages (26, 27).
These mice also show severe deficiency of osteoclasts, result-
ing in impaired bone remodeling and skeletal deformities (25–
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27). Homozygous (
 
op
 
/
 
op
 
) mice have domed skulls and lack
teeth, impairing consumption of solid food. Chronic injection
of recombinant M-CSF partially corrects the phenotypic de-
fects in 
 
op
 
/
 
op
 
 mice (8).
We and others have used these mice fed an atherogenic
diet or crossed with hypercholesterolemic apo E–null mice as a
model to examine the role of M-CSF deficiency on atherogen-
esis, arterial calcification, and atherosclerotic lesion histology
(28, 29). Mice lacking either apo E or LDLR exhibit hypercho-
lesterolemia and develop advanced atherosclerotic lesions sim-
ilar to those observed in humans (30–33). Our previous studies
have provided evidence that M-CSF deficiency in mice fed an
atherogenic diet or having an apo E–null genotype results in
reduced fatty streak development and atherosclerosis but in-
creased arterial calcification (28, 29). This report describes
findings regarding the effects of M-CSF deficiency on athero-
sclerosis in the LDLR-null mouse, an animal model for human
familial hypercholesterolemia. By crossing LDLR-null mice
with 
 
op
 
/
 
op
 
 mice, we have developed mice strains highly sus-
ceptible to atherosclerosis in which the role of M-CSF defi-
ciency could be assessed. Our present results indicate that
complete M-CSF deficiency in LDLR-null mice also signifi-
cantly reduces atherosclerosis but, most remarkably, they
demonstrate concentration-dependent effects of M-CSF ex-
pression on atherogenesis as mice heterozygous for the 
 
op
 
 mu-
tation exhibited an 
 
z
 
 100-fold decrease in lesion size. The
LDLR-null mice heterozygous for the 
 
op
 
 mutation exhibited
an 
 
z
 
 20% reduction in the number of circulating monocytes as
compared with controls, suggesting that the number of mono-
cytes in circulation may not explain the effect of M-CSF on le-
sion development.
 
Methods
 
Mice.
 
Breeding pairs of homozygous LDLR (
 
2
 
/
 
2
 
) mice on a C57BL/
6J background and heterozygous (
 
op
 
/
 
1
 
) mice on a C57BL/6J 
 
3
 
C3HeB/FeJ hybrid genetic background were purchased from The
Jackson Laboratory (Bar Harbor, ME). Heterozygous (
 
op
 
/
 
1
 
) mice
were subsequently backcrossed for four generations to inbred strain
C57BL/6J mice (28) to produce a homogeneous genetic background.
Mice were housed in a virus antibody-free environment, maintained
in a temperature-controlled room with a light/dark cycle and fed a
modified AIN76A (28, 34) diet (Research Diet, New Brunswick, NJ)
with free access to water for 12 wk after weaning. Mice lacking M-CSF
(
 
op
 
/
 
op
 
) were fed powdered diet in a liquid suspension using a glass
feeding tube to optimize food intake and growth during the period af-
ter weaning (28). At the age of 3 mo, control C57BL/6J mice, het-
erozygous (
 
op
 
/
 
1
 
) mice, and homozygous (
 
op
 
/
 
op
 
) mice on the C57BL/
6J background were fed with the atherogenic diet for 16 wk. The
atherogenic diet (TD 90221; Food-Tek, Inc., Morris Plains, NJ) con-
tained (wt/wt) 15% fat, 1.25% cholesterol, and 0.5% cholic acid (28).
 
Genotyping.
 
Tail tips were digested in solution containing SDS
and proteinase K, and DNA was extracted by phenol-chloroform,
precipitated, and stored at 
 
2
 
20
 
8
 
C. For genotyping, we performed
PCR assays using different sets of primers specific for 
 
op
 
 or LDLR al-
leles as described (28, 32). PCR reactions were generally performed
using 50 ng DNA at 30–35 cycles in the presence of 100 nM of each
primer. Each cycle consisted of 0.5 min at 95
 
8
 
C, annealing for 0.5 min
at 60
 
8
 
C, and elongation for 1 min at 72
 
8
 
C. The 
 
op
 
 allele genotyping
was performed in the presence of radiolabeled [
 
32
 
P]dATP and the
PCR products were separated on a 12% polyacrylamide-urea DNA
sequencing gel. The bands were visualized by autoradiography. PCR
products for wild-type and mutant LDLR alleles were visualized by
agarose gel electrophoresis in the presence of ethidium bromide. In
 
certain circumstances, we also used the Southern blotting method for
genotyping. Briefly, 5–10-
 
m
 
g samples of each DNA preparation from
normal and mutant mice were subjected to restriction enzyme diges-
tion, agarose gel electrophoresis, and transfer to nylon filters fol-
lowed by cross-linking by ultraviolet irradiation. Under standard con-
ditions, filters were hybridized with specific probes, washed, and
autoradiographed.
 
Blood monocyte, M-CSF ELISA, and lipid analysis.
 
Blood from
overnight fasted mice was collected from retroorbital plexus into a
tube containing EDTA. Blood smears on glass slides were prepared
immediately for monocyte counting. The dried smears were stained
with Diff-Quik (Baxter Healthcare Corp., Deerfield, IL), and mono-
cytes were determined from a minimum of 100 white blood cells as
described (29). Plasma was collected by centrifugation at 4
 
8
 
C. Con-
centration of M-CSF in mice serum was determined using an ELISA
developed in our laboratory with a polyclonal rabbit anti–M-CSF an-
tibody (35). Plasma concentrations of total and HDL cholesterol
were measured in duplicate or triplicate by an enzymatic assay (28,
33). Mouse plasma lipoproteins were fractionated by FPLC as de-
scribed previously (36). Plasma fractions were pooled for each geno-
type in equal proportion from all mice within each group and 0.2 ml
was applied to the column. Cholesterol content was determined in
100-
 
m
 
l aliquots of each 0.5-ml FPLC fraction (36).
 
Qualitative and quantitative analyses of atherosclerotic lesions.
 
Methods for the qualitative and quantitative analyses of atheroma-
tous lesions in the aorta have been reported previously (28, 33).
Briefly, mice were killed by cervical dislocation at 7 mo of age. The
heart and proximal aorta (including ascending aorta, aortic arch, and
a portion of descending aorta) were excised and washed in PBS to re-
move blood. The basal portion of the heart and proximal aorta were
embedded in OCT compound (Tissue-Tek, Elkhart, IN), frozen on
dry ice, and then stored at 
 
2
 
70
 
8
 
C until sectioning. Serial 10-
 
m
 
m-thick
cryosections (every fifth section from the lower portion of the ventri-
cles to the appearance of aortic valves, every other section in the
region of the aortic sinus, and every fifth section from the disappear-
ance of the aortic valves to the aortic arch) were collected on poly-
 
D
 
-lysine–coated slides. Sections were stained with oil red O and he-
matoxylin and counterstained with fast green for the identification of
atheromatous lesions, arterial wall calcification, and cartilaginous
metaplasia (28, 33, 37). The presence of calcium deposits was con-
firmed by the alizarin red S and von Kossa techniques using represen-
tative sections.
 
Statistical analysis.
 
Data analysis was performed using Statview
(Student’s 
 
t
 
 test and ANOVA) software for the Macintosh. The
threshold of significance for multiple comparisons among various
groups of mice was adjusted according to the Bonferroni method us-
ing the formula for the adjusted level of significance: 0.1/(2 
 
3
 
 number
of comparisons).
 
Results
 
Breeding and genotyping.
 
We intercrossed heterozygous (
 
op
 
/
 
1
 
)
males with homozygous LDLR (
 
2
 
/
 
2
 
) females following the
experimental strategy described previously (28). Half of the
offspring of this cross were heterozygous for both M-CSF and
LDLR mutations. The first generation was screened for the 
 
op
 
and LDLR mutations by using PCR on the genomic DNA iso-
lated from the tail tips. Identified double heterozygotes for
both LDLR and M-CSF were interbred by brother–sister mat-
ing to obtain homozygous (
 
op
 
/
 
op
 
), heterozygous (
 
op
 
/
 
1
 
), and
control (
 
1
 
/
 
1
 
) mice on an LDLR-null genotype. To enhance
the yield of double nulls (
 
op
 
/
 
op
 
, LDLR-null), heterozygous
 
op
 
/
 
1
 
 brothers and sisters on LDLR-null background were in-
terbred.
Animal husbandry of the mice that lacked either M-CSF or
M-CSF and LDLR was very critical. These mice were initially 
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raised for 12 wk on a semipurified cholesterol-free AIN76A
diet (28, 34). The diet was modified to allow feeding as a liquid
suspension in order to optimize growth and survival in these
mice with poor dentition after weaning. M-CSF–deficient 
 
op
 
/
 
op
 
 mice do not grow as well as 
 
op
 
/
 
1
 
 or 
 
1
 
/
 
1
 
 mice even before
weaning. We suspect that this is due to their inability to com-
pete with normal littermates for milk from the dam. Our stud-
ies show that the 
 
op
 
/op mice have the capacity to grow at a
rate equivalent to normal after weaning if the mice are isolated
from normal littermates and fed a nutritionally complete and
readily consumable diet. As described previously, there were
compensatory weight gains in the op/op mice during 0– 4 wk of
feeding after weaning as compared with normal littermates
(28).
M-CSF deficiency augments hypercholesterolemia and re-
duces monocyte numbers in LDLR-null mice. When LDLR-
null mice of op/op genotype consumed an atherogenic choles-
terol- and cholate-supplemented diet, they exhibited enhanced
hypercholesterolemia compared with littermates having either
1/1 or op/1 genotypes (Fig. 1, A and B). Total plasma choles-
Figure 1. (A) Effects of 
M-CSF deficiency on the 
total plasma cholesterol in 
LDLR-null mice main-
tained on a high-fat, high-
cholesterol atherogenic 
diet. Genotypes were 
used as group variables. 
Values are expressed as 
mean6SEM. *P , 0.001. 
(B) FPLC separation of 
the LDLR-null mice plas-
mas having genotypes op/
op, op/1, or 1/1 for
M-CSF gene mutation. 
Plasma fractions were 
pooled for each genotype 
in equal proportion from 
all mice within each group 
and 0.2 ml was applied to 
the column. Cholesterol 
content was determined 
in 100-ml aliquots of each 
0.5-ml FPLC fraction. The 
bars indicate the volumes 
in which VLDL, LDL, 
and HDL elute from the 
column.Role of M-CSF in Atherosclerosis 2705
terol levels in the double mutant mice averaged z 2,200 mg/dl
in the op/op, z 50% higher than hypercholesterolemic LDLR-
null littermates. The cholesterol in each of the groups was pri-
marily in VLDL, IDL, and LDL. The levels of HDL choles-
terol in all genotypes were comparable, averaging z 84 mg/dl
(Fig. 1 B). There were no significant gender influences on the
total and HDL cholesterol. Monocyte differential counts in the
LDLR-null mice showed that total absence of M-CSF resulted
in reduced number of peripheral blood monocytes to less than
half as compared with mice having full M-CSF activity. LDLR-
null littermates of genotypes from op/op, op/1, to 1/1
showed a gene dosage effect having monocyte differentials of
z 4.5, 8, and 10%, respectively (Fig. 2). The concentration of
M-CSF in the sera of op/1 mice was 65% of that in 1/1, and
op/op mice showed a complete absence of circulating M-CSF
(Table I).
Partial as well as total absence of M-CSF in hypercholester-
olemic LDLR-null mice decreases atherosclerosis. The diet-
induced atherosclerosis in LDLR-null mice without op muta-
tion was severe, particularly in the aortic root, ascending aorta,
and aortic arch (Figs. 3 and 4). We quantitated the aortic
atheromatous lesions in mice with three different genetic com-
binations of mutations in the M-CSF and LDLR loci (Table II
and see Fig. 5). Four double mutant mice (two males and two
females) were almost free of fatty lesions in the aortic root, as-
cending aorta, and aortic arch (Fig. 3, a and b, and Fig. 4, a and
c). Thus, the homozygous M-CSF mutation, genotype op/op,
significantly reduced the development of atheromatous lesions
in these regions (Table II and Figs. 3–5). The mice heterozy-
gous for the M-CSF mutation (op/1) also exhibited remark-
ably reduced atheromatous lesion formation (Fig. 3, c and d,
and Table II). After 16 wk of the atherogenic diet, the diet-
induced atheromatous lesions in the aortic root of op/1 mice
were much smaller than those of LDLR-null mice (Table II
and Fig. 3). There were no advanced lesions (with fibrous cap)
in op/1 mice on this genetic background. Among LDLR-null
mice, the frequency of atherosclerosis in the aortic arch was
0/4 in the presence of homozygous op mutation, 0/10 in the
presence of heterozygous op mutation, and 10/12 in the ab-
sence of op mutation.
Discussion
This study shows that absence of M-CSF in LDLR-null mice
fed a high-fat, high-cholesterol diet augments hypercholester-
olemia but significantly reduces formation of atherosclerotic
lesions. These results agree with previous studies of athero-
sclerosis in M-CSF–deficient mice fed an atherogenic diet or
on a hypercholesterolemic apo E–null background (28, 29).
These results also emphasize two important additional conclu-
sions. First, the effect of M-CSF expression is clearly concen-
tration-dependent, since mice heterozygous for the op muta-
tion express 35% lower than normal levels of M-CSF (26, 27,
Table I) yet they exhibit , 1% of the lesion development of
LDLR-null mice with two normal M-CSF alleles. Second, our
results suggest that the effect of the M-CSF mutation on
atherogenesis is not mediated by effects on the number of cir-
culating monocytes, since in heterozygous mice the number of
circulating monocytes was decreased by only z 20%, whereas
the lesion volume decreased by . 100-fold. The effects of the
op mutation on lesion development were more striking in this
study than in previous studies using diet-induced atherosclero-
sis or an apo E–null model (28, 29). Presumably, this resulted
from the LDLR-null background in the present study, al-
though another confounding effect could be the noninbred ge-
netic backgrounds used in some of the previous studies. The
lesions observed in this study were also substantially larger
than those previously studied. The effect of heterozygous op
mutation was particularly striking on LDLR-null backgrounds;
for example, whereas Smith et al. (29) observed a , 40% de-
crease in lesions in op/1 mice as compared with 1/1 mice on
an apo E–null background, there was a . 100-fold decrease in
lesions of op/1 mice as compared with 1/1 mice on an
LDLR-null background. There may well be some differences
in lesion development between the dietary, apo E–null, and
LDLR-null models; for example, we have observed that the
early lesions in LDLR-null mice are particularly lipid rich.
Figure 2. Monocyte differential counts in LDLR-null mice having no 
mutation, heterozygous (op/1), or homozygous (op/op) M-CSF mu-
tations. Values are expressed as mean6SEM. Statistical significance 
for genotype effects as analyzed by two-way ANOVA was as follows: 
1/1 vs. op/op, P , 0.001; 1/1 vs. op/1, P , 0.001; op/op vs. op/1,
P , 0.005.
Table I. M-CSF Concentration in Sera of LDLR-null Mice 
Having op/op, op/1, and 1/1 Genotypes
M-CSF 
units/ml
op/op 0 (6)
op/1 9566102 (6)
1/1 14556132 (6)
The number of mice sampled per group is given in parentheses. Values
are represented as the means6SD of results of duplicate assays on sam-
ples derived from individual mice. 1 unit of M-CSF is equivalent to 13
pg of protein.2706 Rajavashisth et al.
Figure 3. Effect of op mutation on atheromatous lesions in LDLR-null mice. All sections were from mice homozygous for the LDLR-null muta-
tion. (a) Cross-section of aortic root from op/op mouse showing aortic wall with no evidence of fatty lesion formation. 312.5. (b) High-power 
view of a showing a normal valve attachment and its related aortic wall. 350. (c) Cross-section of aortic root from op/1 mouse showing a raised 
type II lesion in free aortic wall (arrow) and a type I lesion in valve attachment (arrowhead). 312.5. (d) High-power view of c showing raised 
type II lesions in free aortic wall. 350. (e) Cross-section of aortic root from 1/1 mouse (no op mutation) showing advanced type I and type II le-
sions. 310. (f) High-power view of e showing a large advanced type II lesion with fibrous cap (arrowhead) and necrotic core (N). 350. Mice were 
maintained on a high-fat, high-cholesterol diet for 16 wk. All sections were stained with oil red O, hematoxylin, and fast green.Role of M-CSF in Atherosclerosis 2707
If the effect of M-CSF on lesion formation is not attributed
to levels of circulating monocytes or lipoprotein particles, it
presumably results from effects on the functional properties of
circulating monocytes or effects at the level of the vessel wall.
It is possible that there is heterogeneity in the circulating
monocytes and that classes of monocytes contributing to the
lesion formation are reduced to a greater extent. We have
shown previously that oxidized LDL particles substantially in-
duce M-CSF in endothelial cells and that M-CSF expression is
elevated in atherosclerotic lesions as compared with the nor-
mal artery wall (11, 12). Since monocyte migration from the ar-
terial lumen to the subendothelial space occurs in the initial
stages of atherosclerosis, it is likely that augmented expression
of M-CSF in the vessel wall, in combination with the increased
expression of other monocyte chemotactic and adhesion mole-
cules such as VCAM-1 and MCP-1, results in enhanced migra-
tion of monocytes to the subendothelial space. It is noteworthy
that all the cells of the vessel wall, including endothelial cells,
smooth muscle cells, and monocyte-macrophages, are capable
of producing M-CSF. The observation that human M-CSF
stimulates the expression of MCP-1 and increases the adhesion
of monocytes to endothelial monolayers further supports this
conclusion. The presence of M-CSF in the vessel wall may also
stimulate the differentiation of newly recruited monocytes into
macrophages. Macrophages proliferate within atherosclerotic
lesions and M-CSF stimulates the proliferation and survival of
macrophages in culture and in vivo, suggesting that its induced
expression in atherosclerotic lesion may also directly stimulate
the proliferation of monocyte-macrophages. The ability of
M-CSF to enhance the uptake and degradation of modified li-
poproteins and cholesterol esterification, possibly by augment-
ing scavenger receptors, may lead to lipid loading of macro-
Figure 4. Effect of op mutation on fatty lesion formation in ascending aorta and aortic arch of LDLR-null mice. All mice were homozygous for 
the LDLR-null mutation. (a) Cross-section of ascending aorta from op/op mouse showing no evidence of atheromatous lesion. 312.5. (b) Cross-
section of ascending aorta from 1/1 (no op mutation) mouse showing a large advanced atheromatous lesion (arrowheads). 313. (c) Cross-sec-
tion of aortic arch from op/op mouse showing no evidence of atheromatous lesion. 325. (d) Cross-section of aortic arch from 1/1 (normal
M-CSF gene) showing atheromatous plaques (arrowheads). 325. Mice were maintained on a high-fat, high-cholesterol diet for 16 wk. All sec-
tions were stained with oil red O, hematoxylin, and fast green.2708 Rajavashisth et al.
phages to form foam cells. The role of M-CSF in promoting the
survival of lipid-loaded foam cells may be critical in the early
and advanced stages of atherosclerosis. M-CSF may also influ-
ence the growth or function of smooth muscle cells (38). It is
possible that monocytes in op/op or op/1 are not activated to
extravasate and scavenge lipid, independent of any effect of
vessel wall M-CSF. Additionally, monocytes in the mutant
mice may have defective chemotaxis and may be incapable of
responding to other chemokines and adhesion molecules. Fur-
ther experiments are needed to test these possibilities.
The striking concentration dependence of lesion develop-
ment on M-CSF expression in the present studies suggests a
threshold effect. The fact that op/1 mice express z 65% of
normal levels of M-CSF (Table I) yet exhibit , 1% of the le-
sion development of LDLR-null mice with two normal M-CSF
alleles indicates that a minimal amount of M-CSF is required
for rapid progression of atherogenesis. The present data show
that even in the presence of hypercholesterolemia, a 35% de-
crease in M-CSF levels does not appreciably influence the
number of circulating monocytes or the number of monocyte-
macrophage progenitor cells in the bone marrow (26, 27). The
substantial induction of M-CSF that occurs in atherosclerotic
C57BL/6J mice, but not in resistant C3H mice, fed an athero-
genic diet (15), suggests that M-CSF may contribute to genetic
differences on lesion development in dietary models. Perhaps
the level of M-CSF expression in the artery wall of op/1 mice
is insufficient to permit proliferation or survival of vascular
monocyte-macrophages.
Numerous studies have documented large differences in le-
sion size between male and female C57BL/6 mice. The mecha-
nisms of this remain unclear, although it is related to sex hor-
mones, since implanting testosterone pellets in female mice
decreased lesion development (39). It should be noted that ge-
netic differences similarly influence lesion sizes in males and
females. Thus, for example, male apo E–null mice develop
fewer lesions than female apo E–null mice, but in both genders
lesion development is dramatically elevated as compared with
wild-type mice. Previous studies with op/op mice have gener-
ally been complicated by the effects of M-CSF deficiency on
nutritional status and by the mixed genetic background of
commercially available mice (28, 29). A mixed genetic back-
ground may contribute to the observed results because of geno-
type variability. We minimized this problem in our experi-
ments by transferring the op mutation to an inbred (C57BL/
6J) genetic background through selective breeding. Poor den-
tition in op/op mice poses the major problem of adequate food
Table II. Atherosclerosis in LDLR Knockout and op/op Mice Fed an Atherogenic Diet
Genotypes Sex (n)
Fatty lesions in
aortic root
Occurrence
of lesion in
aortic arch
Occurrence 
of aortic
calcification Raised lesions
Advanced
lesions
% of aortic
lesion of LDLR
2/2, 1/1
mm2/section
LDLR 2/2, 1/1 M (5) 10641256140467 4/5 (80%) 4/5 (80%) 5/5 (100%) 5/5 (100%)
F (7) 14435006322472 6/7 (86%) 6/7 (86%) 6/7 (86%) 6/7 (86%)
Total (12) 12854276198133 10/12 (83%) 10/12 (83%) 11/12 (92%) 11/12 (92%) 100%
LDLR 2/2, op/op M (2) 526665172 0/2 (0%) 0/2 (0%) 1/2 (50%) 0/2 (0%)
F (2) 247761430 0/2 (0%) 0/2 (0%) 1/2 (50%) 0/2 (0%)
Total (4) 387162334 0/4 (0%) 0/4 (0%) 2/4 (50%) 0/4 (0%) 0.3%
LDLR 2/2, op/1 M (5) 4006193 0/5 (0%) 0/5 (0%) 0/5 (0%) 0/5 (0%)
F (5) 1475067745 0/5 (0%) 0/5 (0%) 3/5 (60%) 1/5 (20%)
Total (10) 757564366 0/10 (0%) 0/10 (0%) 3/10 (30%) 1/10 (10%) 0.6%
Aortic lesions are expressed as mean6SEM. ANOVA among different strains was as follows: LDLR 2/2, 1/1 vs. LDLR 2/2, op/op, P , 0.01;
LDLR 2/2, 1/1 vs. LDLR 2/2, op/1, P , 0.01; LDLR 2/2, op/op vs. LDLR 2/2, op/1, P , 0.01. As multiple comparisons of these data were
performed, the threshold significance levels should be adjusted. Using the formula for the adjusted level of significance 5 0.1/(2 3 number of compar-
isons), the level of significance for the effect of the op mutation on lesion size in LDLR knockout mice with three groups (op/op, op/1, 1/1) is calcu-
lated as , 0.016.
Figure 5. Quantitative comparisons of atheromatous lesions in mice 
with different combination of op/op and LDLR alleles. Mice were 
maintained on a high-fat, high-cholesterol diet. Method for quantita-
tion of atheromatous lesions in mouse aortic root has been reported 
previously (28, 33). Values were expressed as mean6SEM. *P , 0.01.Role of M-CSF in Atherosclerosis 2709
consumption, as the animals cannot eat solid food. Reduced
growth rates due to malnutrition could clearly contribute to
the reduced atherosclerosis. We made efforts to eliminate this
problem by developing and providing a liquid suspension of a
powdered diet to maintain the body weight of the op/op mu-
tants in the range of 30 g. However, the op/1 mice do have
normal teeth, eating behavior, and growth, indicating that the
problems with food intake do not contribute to reduced ath-
erosclerosis.
Augmented hypercholesterolemia in LDLR-null mice due
to total absence of M-CSF is consistent with previous findings
showing that injection of M-CSF lowers plasma cholesterol
levels (18–22). The induced expression of scavenger receptor
by M-CSF may explain its effect on lowering of plasma choles-
terol levels in humans, nonhuman primates, and hypercholes-
terolemic rabbits (21, 22). M-CSF enhances the clearance of
LDL through both LDLR-dependent and -independent path-
ways in rabbits, stimulates cholesterol esterification in human
monocyte-derived macrophages, and modulates lipoprotein li-
pase secretion in macrophages (21–23). The cholesterol-lower-
ing effects of M-CSF may protect the vessel from developing
atherosclerosis. Thus, the role of M-CSF appears to be para-
doxical in the context of atherosclerosis.
In summary, our data support a crucial role for M-CSF in
atherosclerosis. In particular, heterozygous mice with z 65%
of normal levels of M-CSF have, like op/op mice, dramatically
reduced lesion development. We hypothesize that locally pro-
duced M-CSF in the vessel wall, by influencing the recruit-
ment, growth, survival, and function of monocyte-macro-
phages, may contribute to the development and progression of
atherosclerosis. Additional studies are required to establish
this conclusively. These results agree with the conclusion that
monocyte-macrophages promote atherogenesis and are pre-
requisite for the development of fibrous atherosclerotic le-
sions. M-CSF exists in at least three isoforms and can perform
multiple functions (35, 40–44). The physiologic and pathophys-
iologic significance of multiple M-CSF isoforms and their rele-
vance in vascular disease remain unknown. Genetically altered
mice should prove useful in establishing the role of individual
isoforms of M-CSF in the disease process.
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